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ORIGINAL RESEARCH ARTICLE
Accuracy and consequences of same-day, invasive lung
cancer workup  a retrospective study in patients
treated with surgical resection
Kirsten Riis Madsen1, Asbjørn Høegholm1 and Uffe Bodtger1,2*
1Department of Internal and Respiratory Medicine, Naestved Hospital, Naestved, Denmark; 2Institute of
Regional Health Research, University of Southern Denmark, Odense, Denmark
Background: Though widely used, little is known about accuracy and efficacy of same-day, invasive workup of
suspected lung cancer.
Objective: To evaluate the accuracy and efficacy of same-day, invasive lung cancer workup (diagnosis and
mediastinal staging), and to identify differences between patients without (Group A) or with (Group B) need
for resampling.
Methods: A retrospective study was performed on all consecutive patients referred for surgical treatment for
localised lung cancer after invasive diagnostic and staging workup at our unit. Data were extracted from
electronic medical files. Surgical specimens served as gold standard for correct diagnosis and stage.
Results: A total of 129 patients (peripheral lesion: 84%; mediastinal staging: 97%) were included. After same-
day, invasive workup, 71% had no need for further invasive workup (Group A), while 29% had (Group B).
Group A differed significantly from Group B in fewer invasive tests, fewer days from referral to surgery, and
lower pneumothorax incidence, while no differences were observed in diagnostic accuracy, cancer subtype,
tumour size, tumour stage, peripheral lesion, nodal involvement, gender, or presence of chronic obstructive
pulmonary disease. Tumour located in right upper lobe was associated with need for resampling.
Discussion: Our retrospective study suggests that same-day, invasive workup for lung cancer is safe, accurate,
and efficacious in reducing time to therapy, even in patients with small lesions and low tumour burden.
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P
rimary lung cancer is the second most incident
cancer in both men and women, and is worldwide
the most common cause of cancer-related deaths
(1, 2). Correct diagnosis and staging is pivotal for optimal
treatment as treatment modality and prognosis differ
significantly according to tumour type and dissemination,
staged according to the Union for International Cancer
Control (UICC) tumourlymph nodemetastasis (TNM)
classification system (3, 4). Furthermore, time from diag-
nosis to surgical resection increased from 1995 to 2005 in
the United States (5); thus, there is a need for initiatives to
reduce this avoidable delay.
Surgical resection is offered for patients with localised
disease, documented by radiographic and endoscopic
staging (3). Tissue sampling for cytology or histology is
mandatory, and has generally high specificity regardless
of tumour type or stage, whereas diagnostic sensitivity
and negative predictive value decrease with lesion size (6).
Thus, diagnostic workup of patients eligible for curative
treatment is associated with the lowest diagnostic sensitiv-
ity (6, 7). No single, invasive procedure alone can diagnose
and stage lung cancer in patients with radiologically evident
localised disease (3, 6, 7). The evidence of the combined
diagnostic efficacy of the multiple invasive tests performed
in a single session is sparse, whereas very solid for each
individual diagnostic procedure (6, 8).
The focus of this retrospective study was to investigate
the accuracy and safety of a combined diagnostic approach
in patients with surgically resected non-small cell lung
cancer (NSCLC) with surgical specimens being the gold
standard of diagnosis and stage.
Methods
Design
A retrospective, non-interventional, data collection study
was performed on the basis of electronic medical data
charts.
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Major endpoint
Accuracy of lung cancer workup: % correct cytopatholo-
gical diagnosis and tumour and nodal (TN) stage decided
at multidisciplinary team (MDT) conference compared to
Gold Standard (postsurgical histopathological diagnosis
and TN stage) including intergroup differences (Group
A: patients with completed diagnosis and staging after a
single visit; Group B: patients requiring 2 visits).
Minor endpoint
Intergroup differences in time from referral to diagnosis are
surgery, demographic data, imaging data, tobacco pack
years, airflow obstruction, number and nature of proce-
dures performed, comorbidity, and performance status.
Definition
A ‘conclusive workup (diagnosis and staging)’ was ob-
tained when a determinate TNM stage was decided at the
MDT conference.
Patients
The study included all patients from our institu-
tion (Department of Pulmonology, Naestved Hospital,
Denmark) who underwent invasive diagnostic workup
and were later referred for intended curative surgery for
lung cancer.
The study period was 1 January 2009 to 31 December
2011. A total of 937 patients were diagnosed with lung
cancer in our unit during the study period.
Diagnostic centre
All patients were initially referred for diagnosis and staging
of suspected lung cancer to our institution where experi-
enced pulmonologists, radiologists, cytopathologists, and
oncologists are available with rapid access to computerised
tomography (CT) and positron emission tomography
with low-dose CT (PET-CT). Inter-hospital agreements
provide access to surgical procedures at the Department
of Thoracic Surgery at University Hospitals in either
Odense or Copenhagen (Denmark). In our unit, we per-
form bronchoscopies, endobronchial ultrasound (EBUS),
and/or endoscopic ultrasound (EUS) as outpatient proce-
dures in conscious sedation (intravenous midazolam and
fentanyl). Furthermore, we perform ultrasound-, X-ray-,
or CT-guided transthoracic needle aspiration biopsies
(TTNABs); pleurocenteses; and non-endoscopic, non-
thoracic, ultrasound-guided biopsies (fine-needle aspira-
tion [FNA] biopsies from liver, spleen, skin tumours, bone
lesions, or superficial lymph nodes) in local analgesia.
Diagnostic workup
Briefly, only experienced pulmonologists were involved in
lung cancer workup. Visit 1 was defined as the first visit
with invasive tissue sampling. At our unit, visit 1 included
medical history (including Charlson’s index of comor-
bidity), physical examination [including ECOG (Eastern
Cooperative Oncology Group) performance), spirometry,
tissue sampling, and lastly informing patient of the pre-
liminary results and suspicion (including macroscopic
findings).
Pre-operative staging
Conclusive results were presented at the local MDT
conference with attendance of local pulmonologist, radi-
ologist, cytopathologist, oncologist, and a thoracic sur-
geon (later presented by video transmission). TNM stage
was assessed (9), and patients were referred to relevant
therapy according to cytology, TNM, and performance
status (10).
The post-surgical diagnosis and stage was considered
the gold standard of TN stage.
Ethics
This study was a retrospective observational study aimed
to examine the quality of previously performed proce-
dures. There was no randomisation, intervention, or study-
specific collection of biological material, and thus the
study do not fall under the jurisdiction of ethics committee
system. Data collection was approved by The Danish Data
Protection Agency.
Data analysis
All data were collected from medical records. Each visit
to Naestved Hospital that included an invasive proce-
dure (excluding blood sampling) was noted and counted.
All statistical analyses were performed using commer-
cially available software (SPSS version 20, IBM, USA).
Discrete data were presented as median (range), and
binary data as percentage. Differences were examined
with non-parametric testing (MannWhitney U-test and




A total of 133 patients were referred for surgery (14%
of the 937 patients diagnosed with lung cancer during the
study period). Four patients were excluded: pre-operative
staging (after neo-adjuvant chemotherapy) performed
by thoracic surgeons (n1), or no invasive diagnostic
procedures performed (small, peripheral lesions, and
radiographically normal mediastinal lymph nodes; n3).
Table 1 depicts data on the 129 included patients
(female64; median age69 [range 1984] years). We
found no gender- or age-related differences concerning
any variable (data not shown).
Lung cancer workup
Definite diagnosis and stage as decided at the MDT
conference was achieved in 91 patients (71%) after a single
visit. At visit 1, patients went through a bronchoscopy
(97%), EBUS (98%), and TTNAB (78%), and additionally
Kirsten Riis Madsen et al.
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16 patients (12%) had either a EUS-FNA of the left
adrenal gland (n12) or an ultrasound-guided FNA of
liver lesion (n3) or cervical lymph node (n1) in our
endoscopy unit.
Resampling was needed in 38 patients (29%) because of
inconclusive diagnosis (n23; 18%), conclusive diagnosis
but EBUS not representative (n9; 7%), both (n1; 1%),
no EBUS at visit 1 (n2; 2%), EBUS sample adequate
and benign from PET-positive node (n2; 2%), and
abnormal cells in N2 lymph node (n1; 1%): re-
bronchoscopy (once: n12 patients; twice: n1); re-
EBUS (once: n17 patients), and TTNAB (once: n14;
twice: n2).
Workup included both a contrast-enhanced CT and
a PET-CT in most patients (n122; 97%). Contrast-
enhanced CT alone (n3) or PET-CT alone (n4) was
not associated with the need for resampling (Table 2). PET-
scan resulted in additionally eight diagnostic procedures
(Group A: n6 [6%]; Group B: n2 [6%]): mammography
(n2), gastro-duodenoscopy (n2), sigmoidoscopy
(n3), and brain MR (n1).
Having a tumour in the right upper lobe was associated
with need for resampling (p0.014). We found no
significant association between tumour localisation in
right versus left lung nor in upper lobes versus middle/
lower lobes and need for resampling.
Table 3 shows incidence and spectrum of complica-
tions. There were no serious adverse events to workup.
Diagnosis and stage
Pre-operatively, a total of 120 (93%) patients were diag-
nosed with primary lung cancer: adenocarcinoma (n64;
50%), squamous cell carcinoma (n31; 24%), NSCLC/
Carcinoma not otherwise specified (NOS; n17; 13%),
carcinoid (n4; 3%), and neuroendocrine non-carcinoid
tumours (n4; 3%) without any significant differences
between Group A versus B. The remaining nine patients
(7%) had persistent and PET-positive lesions without
conclusive cytopathological diagnosis despite targeted
workup (Table 2). Chronic inflammation, and not malig-
nancy, was found after lobectomy in one of these undiag-
nosed patients (Group B). Table 4 depicts differences in
pre- and post-operative tumour (T) and nodal (N) stage.
Totally, 99 patients had a matching pre-and post-
surgical diagnosis (Group A: n70 [77%] vs. Group B:
n29 [76%]; p0.5). In the remaining patients, most
Table 1. Demographic and basic clinical data on patients with completed workup (Group A) versus incomplete workup (Group B)
after multiple invasive tests at a single visit
51 visit, n91 (Group A) ]2 visit, n38 (Group B) pa
Female, n (%) 49 (54%) 15 (40%) n.s.
Age, median (SD) 68 (3784) 69 (1979) n.s.
Asymptomatic, n (%) 36 (40%) 14 (37%) n.s.
Formerly cancer afflicted, n (%) 23 (25%) 3 (8%) 0.03
Pack years, median (range) 40 (080) 40 (080) n.s.
Smoking status n.s.
Smoker, n (%) 47 (52%) 17 (45%)
Former smoker, n (%) 40 (44%) 18 (47%)
Never smoker, n (%) 4 (4%) 3 (8%)
Chronic obstructive lung disease 46 (64%) 14 (52%) n.s.
FEV1% predicted, median (range) 77 (36145) 82 (23133) n.s.
ECOG performance, median (range) 1 (01) 0 (02)
Charlson’s index, median (range) 1 (08) 1 (04) n.s.
CT, n (%) 87 (96%) 37 (97%) n.s.
PET-CT, n (%) 89 (98%) 37 (97%) n.s.
PET mediastinal lymph nodes, n (%) 15 (17%) 8 (21%) n.s.
Tumour mean diameter, median (range) 30 (10100) 38 (1483) 0.09
Tumour size 520 mm, n (%), 22 (24%) 7 (18%) n.s.
Peripheral lesion 75 (82%) 33 (87%) n.s.
Lobe affected 0.038
Right upper 21 (23%) 17 (45%)
Right middle 3 (3%) 2 (5%)
Right lower 23 (25%) 4 (11%)
Left upper 28 (31%) 6 (16%)
Left lower 16 (17%) 9 (24%)
aCategorical variables: chi-square or Fisher’s test; discrete variables: MannWhitney U-test; n.s: non-significant.
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disagreements were observed in patients with a pre-surgical
diagnosis of carcinoma NOS or no cancer: adenocar-
cinoma (n14; 47%) and squamous cell carcinoma (n5;
17%). Only one was found to have a metastasis from an
extrapulmonary malignancy (Group A): a young woman
with no PET-positive extra-thoracic lesions, and a pre-
surgical diagnosis of large cell carcinoma indistinguishable
from choriocarcinoma metastasis. Histopathological ex-
amination of the resected tumour confirmed the latter.
Table 2 shows that conclusive workup after a single visit
was associated with significantly shorter interval from
referral to surgery. Delayed surgery was observed in five
patients because of cardiac comorbidity, trauma, and
patients’ reluctance to proceed to surgery.
Median tumour size and number of patients with
tumour size 520 mm did not differ between groups
(Table 2). Comparing patients with tumour size 520 mm
versus 20 mm, we observed significantly fewer invasive
Table 2. Differences in radiographic findings, number of invasive tests and visits, prevalence of invasive tests, and mortality
between groups
51 visit, n91(Group A) ]2 visit, n38(Group B) pa
Days from referral to final diagnosis (MDT), median (range)
[1090 percentile]
16 (248)[927] 29 (12197)[1346] B0.00001
Days from referral to surgery, median (range) [1090 percentile] 41 (14127)[2866] 49 (21246)[2877] B0.005
Bronchoscopy, n (%) 87 (96%) 37 (97%) n.s.
Diagnostic yield 17% 13% n.s.
EBUS, n (%), 88 (97%) 37 (97%) n.s.
Diagnostic yield 14% 8% n.s.
TTNAB, n (%) 70 (77%) 31 (81%) n.s.
Diagnostic yield 92% 84% n.s.
Total number of invasive test, median (range) 3 (15) 4 (27) B0.00001
TRIO at day 1 67 (74%) 25 (66%) n.s.
Futile TTNAB, n (%) 9 (10%) 1 (3%) n.s.
Pre-surgical cytopathological diagnosis, n (%) 86 (95%) 34 (90%) n.s.
Immunohistochemistry, n (%) n.s.
Performed 54 (59%) 23 (61%)
Microscopy conclusive 12 (13%) 6 (16%)
Not enough material 25 (28%) 9 (24%)
aCategorical variables: chi-square or Fisher’s test; discrete variables: MannWhitney U-test; n.s: non-significant.
Table 3. Demographic and basic clinical data on patients with completed workup (Group A) versus incomplete workup (Group B)
after multiple invasive tests at a single visit
51 visit, n91 (Group A) ]2 visit, n38 (Group B) pa
Visit 1
Complication, n (%) 19 (21%) 7 (18%) n.s.
Pneumothorax, no drain, no admission, n (%) 4 (4%) 1 (3%)
Pneumothorax, no drain, admission, n (%) 5 (6%) 1 (3%)
Pneumothorax, drain, no admission, n (%) 0 (0) 1 (3%)
Pneumothorax, drain, admission, n (%) 7 (8%) 3 (8%)
Other,b n (%) 3 (3%) 1 (3%)
Complication needing admission, n (%) 12 (13%) 4 (11%) n.s.
Days in hospital, median (range) 0 (05) 0 (02) n.s.
Pneumothorax, any, n (%) 14 (15%) 8 (21%) n.s.
All visits
Complication needing admission, n (%) 12 (13%) 7 (18%) n.s.
Pneumothorax, any, n (%) 14 (15%) 13 (34%) 0.017
aCategorical variables: chi-square or Fisher’s test; discrete variables: MannWhitney U-test; bpain, confusion, angina, and vasovagal
hypotension; n.s: non-significant.
Kirsten Riis Madsen et al.
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tests (median 3 [14] vs. 3 [17], pB0.05; mean 2.8 [SD 0.9]
vs. 3.4 [SD 1.0]) but no difference in median time to
surgery (40 [2895] vs. 43 [3170] days, p0.6).
Mortality
Overall mortality 12 months after MDT conference was
16% (n20). One patient in Group A (post-surgical stage
IIbN0M0 squamous cell carcinoma in left lower lobe)
died within the first 48 h after surgery. Table 4 shows that
mortality at 1, 6, or 12 months did not differ significantly
between groups.
Discussion
Bias is unavoidable in retrospective studies, and especially
confounding-by-indication is most likely present in our
retrospective study on everyday practice. Yet, this study is
the first to actually address the efficacy of the widely used
same-day, invasive workup of lung cancer workup, aiming
at reducing the number of patients’ visits. We found that
most patients were successfully diagnosed and staged after
a single visit, implying fewer invasive tests and a reduced
time delay to surgery, without negative impact on
diagnostic accuracy or mortality. Tissue samples were
obtained by endoscopic and/or transthoracic FNA biop-
sies according to individualised plans based on findings at
contrast-enhanced CT and/or PET-CT (low-dose) scan(s).
We reported only surgically resected cases as the gold
standard of lung cancer workup is absent in non-resected
cases. All but one patient had a malignant diagnosis, and
74% was diagnosed and staged after a single visit with
tissue sampling.
In our study, we found that tumour location in right
upper lobe  but neither tumour size or peripheral
location, concomitant chronic obstructive pulmonary
disease, low physical performance, nor PET-positive
mediastinal lymph nodes  was associated with diagnostic
failure (Group B; Table 1). The impact of lobar tumour
location on sensitivity or negative predictive values has
been sparsely investigated. A bronchoscopic study found
the lowest yield when the lesion was in the most apical
or basal segment (11), and a TTNAB study found the
numerically lowest yield in the right upper lobe (12).
The background is not known, but we speculate that the
thoracic anatomy of the apical thorax restricts tumour
Table 4. Differences in pre- and post-operative diagnosis and stage between groups










Adenocarcinoma 45 (50%) 19 (50%) 52 (57%) 22 (60%)
Squamous cell carcinoma 23 (25%) 8 (21%) 26 (29%) 10 (26%)
Carcinoma NOS 14 (15%) 3 (8%) 3 (3%) 0 (0%)
Neuroendocrine carcinomab 1 (1%) 3 (8%) 7 (7%) 4 (11%)
Carcinoid tumour 3 (3%) 1 (3%) 3 (3%) 1 (3%)
Non-malignant diagnosis 5 (6%) 4 (11%) 0 1 (3%)
Stage (benign tumour excluded)
T1a 19 (21%) 5 (13%) n.s. 11 (12%) 2 (5%) n.s.
T1b 16 (18%) 5 (13%) 13 (14%) 3 (8%)
T2a 34 (37%) 9 (24%) 44 (48%) 18 (47%)
T2b 12 (13%) 10 (26%) 12 (13%) 4 (11%)
T3 8 (9%) 6 (16%) 10 (11%) 9 (24%)
T4 2 (2%) 3 (8%) 1 (1%) 1 (3%)
N0 81 (89%) 35 (92%) n.s. 67 (74%) 33 (87%) n.s.
N1 9 (10%) 3 (8%) 13 (14%) 2 (5%)
N2 1 (1%)c 0 (0%) 11 (12%) 2 (5%)
Upstaged    18 (20%) 3 (9%) n.s.
Upstaged to N2 9 (10%) 2 (5%) n.s.
Recurrence within 2 years 23 (25%) 6 (16%) n.s.
Mortality, 30-days, n (%)    2 (2%) 1 (3%) n.s.
Mortality 6-month, n (%) 6 (7%) 4 (11%) n.s.
Mortality 12-month, n (%) 15 (17%) 5 (13%) n.s.
NOS, not otherwise specified.
aChi-square or Fisher’s test; bexcept carcinoid; ca patient with CT-normal but FDG-positive lymph node station 5; n.s: non-significant.
Same-day, invasive lung cancer workup
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access because of, for example, lower ribrib distance and
larger distance from skin to pleura compared to more
distally located lesions. As the right upper lobe is smaller
than the left, a larger proportion is located in this difficult
area.
No single technique allows sufficient tissue sampling
for diagnosis and staging every case of suspected lung
cancer, as size, localisation, and numbers of both primary
and metastatic lesions as well as patients’ performance
vary significantly (4, 6, 13). Endoscopic ultrasonographic
tissue sampling is considered the most cost-effective moda-
lities, but cannot reach peripheral stage I or II lung cancer
(14). The diagnostic yield of each tissue sampling techni-
que is well documented (4, 6), but to our best knowledge,
this is the first study to investigate the composite results
of multiple techniques.
Our study addresses a method to reduce time delay from
referral for cancer workup to treatment (15, 16). The
availability of more efficient equipment is counterweighted
by an increasing demand for correct diagnosis at the
molecular levels in order to provide personalised treatment
(3, 17). The time-consuming pre-operative workup by
PET-CT, endoscopic mediastinal staging, and prediction
of expected post-surgical physiology has resulted in a
decrease in lung resections from 2000 to 2007 in Denmark
(18). An American report showed that waiting times for
surgery increased from 1995 to 2005 for the eight most
common cancers but with a shorter delay when diagnosis
and surgery were performed at the same hospital (5). In
Denmark, lung resection is performed at four departments
of thoracic surgery but lung cancer workup in 14 depart-
ments of pulmonology: the proportion of lung cancer
resections performed within 14 days from referral in-
creased from 69% to 87% from 2000 to 2007, mainly
because of implementation of integrated, cross-sectional
national guidelines for lung cancer workup, and reduction
from 40 to 14 diagnostic departments and from 7 to 4
surgical departments (18). At our unit, we have implemen-
ted initiatives to reduce diagnostic delay: all diagnostic
workup is performed by pulmonologists skilled in thoracic
endoscopy (bronchoscopy, EUS, EBUS) and ultrasound-
guided tissue sampling from pleura, liver, spleen, superficial
lymph nodes, subcutis, and breasts (1921). Additionally,
bi-weekly MDT conferences facilitate rapid referral to
oncology or surgery (5, 16, 18, 22).
Furthermore, our data show that we follow the ACCP
and BTS guidelines recommendation of early mediastinal
staging before surgery (3, 10). A recent US report found
that this was performed only in 21% of patients (23, 24).
Mediastinal workup may not be required in patients with
stage Ia and normal lymph nodes at CT, in which a false-
negative rate of 10% is considered acceptable according
to ACCP guidelines, which also states that mediastinal
sampling or not is ‘a matter of judgment’ (4). Although
ACCP guidelines suggest which tests should follow in-
conclusive tissue samplings (6), there are no recommen-
dations on same-day order of invasive tests. The impact
of bronchoscopy-induced coughing or bleeding on diag-
nostic yield of the next tissue sampling (e.g. x-ray-guided
TTNAB) is unknown, but our results (mainly rural living;
median age 69 years; no physician trained in the United
States) suggest that three or more consecutive, invasive
tests are both safe and efficacious (Tables 1 and 2). This is
consistent with a UK study showing that EBUS is as safe
in elderly (70 years) as in younger patients (25). Thus,
integrating diagnosis and staging in one session increases
likelihood of following guidelines and shortens time
delay but requires organisational factors that allow
individualised workup and care (26).
A strength of our study is that none were lost to follow-
up, resulting in unique data completeness. From our unit,
we referred 14% (133 of the 937 patients) for surgery,
equivalent to the Danish mean (27), and patients were
diagnosed according to guidelines by specialists (23). The
external validity of our study is high but only for patients
referred for intended curative surgery for lung cancer, but
not for the total lung cancer population, or the even larger
population with suspected lung cancer. Thus, we cannot
establish a true yield of same-day, invasive workup in lung
cancer workup. On the contrary, our study included the
patients who were most difficult to diagnose and stage
(3, 6). These patients constitute a minority of the total lung
cancer population, and need the highest number of both
invasive and non-invasive tests to pass the ‘needle’s eye’ of
correct diagnosis (NSCLC), low stage, and sufficient
performance and physiological reserves to recover after
surgery (3, 4, 13). As most lung cancer patients present
with metastatic disease (2, 28) where staging and diagnosis
are often achieved with a single biopsy using the principle
of the least invasive method (6), we believe that a final
diagnosis and stage is achievable in a higher number of
patients than reported here.
In the future, we will study the impact of same-day,
invasive workup in unselected patients with suspected
lung cancer, and compare it to multiple-day workup.
Including data on patient-related outcomes and quality
of life will elucidate patients’ preferences, and data on
health-care expenses will challenge previous findings of
costs being positively related to number of workup visits
(29, 30).
In conclusion, we demonstrated that lung cancer
workup with multiple invasive procedures in one day
including a median of three different invasive techniques
in one session is an efficacious and safe method resulting
in valid results in patients with small tumour burden and
localised disease eligible for surgical resection. Prospective
studies should ascertain workup on an intention-to-
treat basis, and possibly include patient-related outcomes
systematically.
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